

## PATENT COOPERATION TREATY

PCT

## NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To

Commissioner  
 US Department of Commerce  
 United States Patent and Trademark  
 Office, PCT  
 2011 South Clark Place Room  
 CP2 5C24  
 Arlington, VA 22202  
 ETATS-UNIS D'AMERIQUE

in its capacity as elected Office

<b>Date of mailing</b> (day month year) 26 March 2001 (26.03.01)	
<b>International application No.</b> PCT/US00 18758	<b>Applicant's or agent's file reference</b> FP-LJ 4236
<b>International filing date</b> (day month year) 07 July 2000 (07.07.00)	<b>Priority date</b> (day month year) 09 July 1999 (09.07.99)
<b>Applicant</b> REED, John, C.	

1. The designated Office is hereby notified of its election made:

☒ in the demand filed with the International Preliminary Examining Authority on:

06 February 2001 (06.02.01)

☐ in a notice effecting later election filed with the International Bureau on:2. The election ☒ was☐ was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO  
 34, chemin des Colombettes  
 1211 Geneva 20, Switzerland

Facsimile No.: (41-22) 740.14.35

Authorized officer

Zakaria EL KHODARY

Telephone No.: (41-22) 338.83.38

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
18 January 2001 (18.01.2001)

PCT

(10) International Publication Number  
**WO 01/04343 A2**

(51) International Patent Classification<sup>7</sup>: C12Q 1/00

(21) International Application Number: PCT/US00/18758

(22) International Filing Date: 7 July 2000 (07.07.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
09/350,518 9 July 1999 (09.07.1999) US

(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier application:  
US 09/350,518 (CIP)  
Filed on 9 July 1999 (09.07.1999)

(71) Applicant (for all designated States except US): **THE BURNHAM INSTITUTE** [US/US]; 10901 North Torrey Pines Road, La Jolla, CA 92037 (US).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **REED, John, C.** [US/US]; 17044 El Camino Real, P.O. Box 137, Rancho Santa Fe, CA 92067 (US).

(74) Agents: **RAMOS, Robert, T.** et al.; Campbell & Flores, LLP, Suite 700, 4370 La Jolla Village Drive, San Diego, CA 92122 (US).

(81) Designated States (national): AE, AL, AM, AT, AU (utility model), AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, CZ (utility model), DE, DE (utility model), DK, DK (utility model), DM, EE, EE (utility model), ES, FI, FI (utility model), GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KR (utility model), KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (utility model), SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

**Published:**

— Without international search report and to be republished upon receipt of that report.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



**WO 01/04343 A2**

(54) Title: A METHOD FOR DETERMINING THE PROGNOSIS OF CANCER PATIENTS BY MEASURING LEVELS OF BAG EXPRESSION

(57) Abstract: In accordance with the present invention, there are provided methods for determining a prognosis of disease free or overall survival in a patient suffering from cancer. Also provided are methods for predicting the risk of tumor recurrence or spread in an individual having a cancer tumor. Methods for screening a cancer patient to determine the risk of tumor metastasis, methods for determining the proper course of treatment for a patient suffering from cancer; and kits for use in practising the invention methods.

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
18 January 2001 (18.01.2001)

PCT

(10) International Publication Number  
**WO 01/04343 A3**

(51) International Patent Classification<sup>7</sup>: **C12Q 1/68**,  
G01N 33/574

(21) International Application Number: PCT/US00/18758

(22) International Filing Date: 7 July 2000 (07.07.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
09/350,518 9 July 1999 (09.07.1999) US

(63) Related by continuation (CON) or continuation-in-part  
(CIP) to earlier application:

US 09/350,518 (CIP)  
Filed on 9 July 1999 (09.07.1999)

(71) Applicant (for all designated States except US): **THE  
BURNHAM INSTITUTE** [US/US]; 10901 North Torrey  
Pines Road, La Jolla, CA 92037 (US).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **REED, John, C.**  
[US/US]; 17044 El Camino Real, P.O. Box 137, Rancho  
Santa Fe, CA 92067 (US).

(74) Agents: **RAMOS, Robert, T. et al.**; Campbell & Flores,  
LLP, Suite 700, 4370 La Jolla Village Drive, San Diego,  
CA 92122 (US).

(81) Designated States (*national*): AE, AL, AM, AT, AT (utility model), AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, CZ (utility model), DE, DE (utility model), DK, DK (utility model), DM, EE, EE (utility model), ES, FI, FI (utility model), GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KR (utility model), KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (utility model), SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:  
— with international search report

(88) Date of publication of the international search report:  
16 August 2001

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: A METHOD FOR DETERMINING THE PROGNOSIS OF CANCER PATIENTS BY MEASURING LEVELS OF BAG EXPRESSION

(57) Abstract: In accordance with the present invention, there are provided methods for determining a prognosis of disease free or overall survival in a patient suffering from cancer. Also provided are methods for predicting the risk of tumor recurrence or spread in an individual having a cancer tumor. Methods for screening a cancer patient to determine the risk of tumor metastasis; methods for determining the proper course of treatment for a patient suffering from cancer; and kits for use in practising the invention methods.

WO 01/04343 A3

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/18758

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12Q1/68 G01N33/574

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12Q G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

WPI Data, PAJ, EPO-Internal, MEDLINE, BIOSIS, EMBASE, CHEM ABS Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	TANG S-C. ET AL., : "Expression of BAG-1 in invasive breast carcinoma" J. CLIN. ONCOLOGY, vol. 17, no. 6, - June 1999 (1999-06) pages 1710-1719, XP000973837	1,16,25, 27,34, 38,41, 43,46,48
Y	the whole document	49
X	KRAJEWSKI S. ET AL.,: "Prognostic significance of apoptosis regulators in breast cancer" ENDOR RELAT CANCER, vol. 6, no. 1, - March 1999 (1999-03) pages 29-40, XP000973814 see whole doc. esp. abstarct and p. 34, 1.col. 1.par. ff.-p.37 last par.	1,16,25, 27,34, 38,41, 43,46-48
	-/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*G\* document member of the same patent family

Date of the actual completion of the international search

5 February 2001

Date of mailing of the international search report

28/02/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.  
Fax: (+31-70) 340-3016

Authorized officer

Mueller, F

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/18758

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication where appropriate, of the relevant passages	Relevant to claim No
Y	BALLINGER C. ET AL.,: "identification of chip, a novel tetratricopeptide repeat-containing protein that interacts with heat shock proteins and negatively regulates chaperone functions" MOL. CELL. BIOLOGY, vol. 19, no. 6, - June 1999 (1999-06) pages 4535-4545, XP002159196 the whole document	49
A	YANG X. ET AL.,: "differentila expression of antiapoptotic gene BAG-1 in human breast normal and cancer cell lines and tissues" CLIN. CANCER. RESAERCH, vol. 5, July 1999 (1999-07), pages 1816-1822, XP000941979 see whole doc.esp. discussion	1,16,25, 27,34, 38,41, 43,48
A	WO 97 07387 A (BAR SHAVIT RACHEL :HADASIT MED RES SERVICE (IL)) 27 February 1997 (1997-02-27) see whole doc. esp. claims	1-50
A	WO 97 48982 A (CHILDRENS MEDICAL CENTER) 24 December 1997 (1997-12-24) see whole doc. esp. claims	1-50
A	WO 95 13292 A (JOLLA CANCER RES FOUND) 18 May 1995 (1995-05-18) see whole doc. esp. claims	1-50
A	TAKAYAMA S. ET AL.,: "Expression and location of HSP70/Hsc binding anti-apoptotic protein BAG-1 and its variants in normal tissues and tumor cell lines" CANCER RESEARCH, vol. 58, no. 14, - 1998 pages 3116-3131, XP000941973 cited in the application see whole odc. esp. p.3127, 1.col., 1.par.ff., tabel 2,	1-50
P,X	WO 00 14106 A (BURNHAM INST) 16 March 2000 (2000-03-16) see whole doc. esp. claims, and p.23, line 7 ff. and p.37, line 12 ff., cl. 34	1,16,41, 43,46,48

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 00/18758

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9707387	A	27-02-1997	IL 114890 A	17-08-1999
			AU 6667496 A	12-03-1997
			CA 2229108 A	27-02-1997
			EP 0846263 A	10-06-1998
WO 9748982	A	24-12-1997	US 5858681 A	12-01-1999
			AU 723144 B	17-08-2000
			AU 3487497 A	07-01-1998
			CA 2257858 A	24-12-1997
			EP 0922223 A	16-06-1999
			JP 2000513098 T	03-10-2000
			US 6150117 A	21-11-2000
WO 9513292	A	18-05-1995	US 5539094 A	23-07-1996
			AU 687952 B	05-03-1998
			AU 1174295 A	29-05-1995
			CA 2176378 A	18-05-1995
			EP 0742793 A	20-11-1996
			JP 9509304 T	22-09-1997
			US 5686595 A	11-11-1997
			US 5650491 A	22-07-1997
WO 0014106	A	16-03-2000	US 5641866 A	24-06-1997
			AU 6038399 A	27-03-2000

CORRECTED VERSION

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
18 January 2001 (18.01.2001)

PCT

(10) International Publication Number  
**WO 01/04343 A3**

(51) International Patent Classification<sup>7</sup>: **C12Q 1/68**,  
G01N 33/574

(21) International Application Number: PCT/US00/18758

(22) International Filing Date: 7 July 2000 (07.07.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
09/350,518 9 July 1999 (09.07.1999) US

(63) Related by continuation (CON) or continuation-in-part  
(CIP) to earlier application:  
US 09/350,518 (CIP)  
Filed on 9 July 1999 (09.07.1999)

(71) Applicant (for all designated States except US): **THE  
BURNHAM INSTITUTE** [US/US]; 10901 North Torrey  
Pines Road, La Jolla, CA 92037 (US).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **REED, John, C.**  
[US/US]; 17044 El Camino Real, P.O. Box 137, Rancho  
Santa Fe, CA 92067 (US).

(74) Agents: **RAMOS, Robert, T.** et al.; Campbell & Flores,  
LLP, Suite 700, 4370 La Jolla Village Drive, San Diego,  
CA 92122 (US).

(81) Designated States (*national*): AE, AL, AM, AT, AU (utility model), AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, CZ (utility model), DE, DE (utility model), DK, DK (utility model), DM, EE, EE (utility model), ES, FI, FI (utility model), GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KR (utility model), KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (utility model), SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:  
— with international search report

(88) Date of publication of the international search report:  
16 August 2001

(48) Date of publication of this corrected version:  
13 September 2001

(15) Information about Correction:  
see PCT Gazette No. 37/2001 of 13 September 2001, Section II

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: A METHOD FOR DETERMINING THE PROGNOSIS OF CANCER PATIENTS BY MEASURING LEVELS OF BAG EXPRESSION

(57) Abstract: In accordance with the present invention, there are provided methods for determining a prognosis of disease free or overall survival in a patient suffering from cancer. Also provided are methods for predicting the risk of tumor recurrence or spread in an individual having a cancer tumor. Methods for screening a cancer patient to determine the risk of tumor metastasis; methods for determining the proper course of treatment for a patient suffering from cancer; and kits for use in practising the invention methods.



WO 01/04343 A3

**A METHOD FOR DETERMINING THE PROGNOSIS OF CANCER PATIENTS  
BY MEASURING LEVELS OF BAG EXPRESSION**

Portions of the invention described herein were made in the course of research supported in part by NIH grant CA-67329. The Government may have certain rights in this invention.

**FIELD OF THE INVENTION**

The present invention relates generally to determining the risk of progression or spread of cancers.

10

**BACKGROUND INFORMATION**

Prognosis in clinical cancer is an area of great concern and interest. It is important to know the aggressiveness of the malignant cells and the likelihood of tumor recurrence or spread in order to plan the most effective therapy. Breast cancer, for example, is managed by several alternative strategies. One of every nine women currently develops breast cancer at some point in her life. In some cases local-regional therapy is utilized, consisting of mastectomy or lumpectomy with or without radiation, while in other cases when spread of disease is detected or suspected, systemic therapy is instituted, such as chemotherapy or hormonal therapy. Among women with early-stage breast cancers treated with lumpectomy and local radiotherapy, 10-20% will experience local recurrences and 30-40% will develop distant metastatic disease which is often fatal (Fischer et al. 1991, Lancet **338**:327-331).



Current treatment decisions for individual breast cancer patients are frequently based on (1) the number of axillary lymph nodes involved with disease, (2) estrogen receptor and progesterone receptor status, (3) the size of the primary tumor, and (4) stage of disease at diagnosis. It has also been reported that DNA aneuploidy and proliferative rate (percent S-phase) can help in predicting the course of disease. In addition, the overexpression of the HER2/Neu oncoprotein has been shown to predict breast cancer patients at risk for metastatic disease and novel therapeutic strategies have been developed to target this receptor (Slamon et al. U.S. Patent No. 4,968,603; Slamon et al. 1989, Science **244**:707-712). However, even with these additional factors, practitioners are still unable to accurately predict the course of disease for all breast cancer patients. There is clearly a need to identify new markers, in order to separate patients with good prognosis who may not require further therapy from those more likely to recur who might benefit from more intensive treatments.

This is particularly true in the case of breast cancer which has not progressed to the axillary lymph nodes. There is now evidence in prospective randomized clinical trials that adjuvant endocrine therapy and adjuvant chemotherapy beginning immediately after surgical removal of the primary breast tumor can be of benefit in some of these node-negative patients. This has led to official and unofficial recommendations that most if not all node-negative breast cancer patients should be considered for some form of adjuvant therapy. But since the majority (about 70%) of these patients enjoy long-term survival following surgery and/or radiotherapy without further treatment, it may be

inappropriate to recommend adjuvant therapy for all of these patients. Accordingly, there is a need for methods to distinguish those node-negative patients who are "cured" from those destined to recur, such that only the latter are treated. Thus, there is a great need for a general method of predicting tumor recurrence or spread in these patients and in cancer patients in general once a primary tumor is detected. The present invention satisfies these needs and provides related advantages as well.

#### SUMMARY OF THE INVENTION

In accordance with the present invention, there are provided methods for determining a prognosis of disease free or overall survival in a patient suffering from cancer. In one embodiment, it has been found that high levels or "overproduction" of BAG proteins in primary tumor tissue show an unexpected and surprisingly high correlation with lack of tumor recurrence or spread, and therefore long-term disease free or overall survival. Thus, the present invention advantageously provides a significant advancement in cancer management because early identification of patients at risk for tumor recurrence or spread will permit aggressive early treatment with significantly enhanced potential for survival.

Also provided are methods for predicting the risk of tumor recurrence or spread in an individual having a cancer tumor; methods for screening a cancer patient to determine the risk of tumor metastasis; methods for determining the proper course of treatment for a patient suffering from cancer; and kits for use in practicing the invention methods.

### BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows that high BAG-1 Protein levels are associated with longer patient survival in breast cancer patients, as set forth in Example 1. Kaplan-Meier survival curves containing the proportion of early stage breast cancer patients whose tumors contain high (O; referred to in the figure as BAG-1 positive) versus low (●; referred to as BAG-1 negative) levels of BAG-1 protein is plotted against time (years) for overall survival (OS) (top; A) and distant metastasis-free survival (DMFS) (bottom; B).

Figure 2 shows the results of Relapse-Free Survival in breast cancer patients with tumor-position lymph-nodes as set forth in Example 2.

Figure 3 shows the results of Cause Specific Survival in breast cancer patients with tumor-position lymph-nodes as set forth in Example 2.

### DETAILED DESCRIPTION OF THE INVENTION

In accordance with the present invention, methods are provided for determining a prognosis of disease free or overall survival in a patient suffering from cancer, said method comprising:

(a) determining a BAG gene expression level in a cancerous tissue sample from said patient; and

(b) classifying said patient as belonging to either a first or second group of patients, wherein said first group of patients having high levels of expression of the BAG gene is

classified as having a different likelihood of suffering tumor recurrence or spread than said second group of patients having low levels of expression of the BAG gene.

- 5 The invention method takes advantage of a newly discovered correlation between abnormal levels of BAG expression in cancerous cells, and the likelihood of cancer-free survival in patients (see, e.g., the Examples section). The invention method comprises determining the
- 10 level of expression of BAG in the cancerous tissue of a patient. The patient may then be classified as belonging to a first group of patients having high levels of expression of BAG, or alternatively, to a second group of patients having low levels of expression of BAG.
- 15 Determination of the prognosis for the patient suffering from cancer may be made by determining whether the group to which the patient has been assigned correlates with a higher or lower likelihood of disease-free or overall survival with respect to the group to which the patient
- 20 was not assigned.

For example, in one embodiment of the invention, it has been discovered that overproduction or a high level of expression of a BAG gene correlates to patients having a decreased risk of tumor recurrence or

25 spread (e.g., local recurrence or spread and/or metastasis). Thus, in this embodiment, patients belonging to a first group having high levels of expression of a BAG gene are classified as having a decreased risk of tumor recurrence or spread compared to

30 a second group of patients having low levels of expression of a BAG gene. This embodiment is particularly useful in evaluating the prognosis of breast cancer patients.

For example, in this embodiment, when BAG gene expression exceeds a determined basal level (also referred to herein as a reference level), it has been found to become a significant factor in decreased tumor recurrence or spread. When tumor cell determined basal levels are exceeded, a BAG expression level is characterized as "high" or "overproduced" and indicates, particularly in the case of breast cancer, a decreased risk of tumor recurrence or spread. Whereas, the mere presence, without overproduction, of BAG protein expression has not previously been correlated with any risk of tumor recurrence or spread.

In another embodiment of the invention, high levels of expression of a BAG gene correlate to patients having an increased risk of tumor recurrence or spread. Thus, in this embodiment, patients belonging to a first group of patients having high levels of expression of the BAG gene are classified as having an increased risk of tumor recurrence or spread compared to a second group of patients having low levels of expression of the BAG gene.

In yet another embodiment of the invention, low levels of expression of a BAG gene correlate to patients having a decreased risk of tumor recurrence or spread. Thus, in this embodiment, patients belonging to a second group of patients having low levels of expression of the BAG gene are classified as having a decreased risk of tumor recurrence or spread compared to a first group of patients having high levels of expression of the BAG gene.

In another embodiment of the invention, low levels of expression of a BAG gene correlate to patients having an increased risk of tumor recurrence or spread.

Thus, in this embodiment, patients belonging to a second group of patients having low levels of expression of the BAG gene are classified as having an increased risk of tumor recurrence or spread compared to a first group of  
5 patients having high levels of expression of the BAG gene.

The invention methods are useful in the prognosis of disease-free or overall survival of individuals with neoplastic diseases, including both  
10 solid tumors and hematopoietic cancers. Exemplary neoplastic diseases include carcinomas, such as adenocarcinomas and melanomas; and sarcomas, such as various leukemias or lymphomas. Of particular interest are breast cancer, prostate cancer, lung cancer, colon  
15 cancer, leukemia, lymphoma, and oral cancer; more particularly breast cancer.

As used herein, the terms "cancer recurrence" and "tumor recurrence," and grammatical variants thereof, refer to further growth of neoplastic or cancerous cells  
20 after diagnosis of cancer. Particularly, recurrence may occur when further cancerous cell growth occurs in the cancerous tissue. "Tumor spread," similarly, occurs when the cells of a tumor disseminate into local or distant tissues and organs; therefore tumor spread encompasses  
25 tumor metastasis.

As used herein, the phrase "disease-free survival," refers to the lack of such tumor recurrence and/or spread and the fate of a patient after diagnosis, with respect to the effects of the cancer on the  
30 life-span of the patient. The phrase "overall survival" refers to the fate of the patient after diagnosis, despite the possibility that the cause of death in a

patient is not directly due to the effects of the cancer. The phrases, "likelihood of disease-free survival", "risk of recurrence" and variants thereof, refer to the probability of tumor recurrence or spread in a patient  
5 subsequent to diagnosis of cancer, wherein the probability is determined according to the process of the invention.

Depending on the nature of the cancer, an  
10 appropriate patient sample is obtained. As used herein, the phrase "cancerous tissue sample" refers to any cells obtained from a cancerous tumor. In the case of solid tumors which have not metastasized, a tissue sample from the surgically removed tumor will typically be obtained  
15 and prepared for testing by conventional techniques. Alternatively, a body fluid sample, such as a lymph, blood or serum sample, or an exudate fluid sample such as the cancerous organ exudate (e.g., exudate from the breast) may be collected and used as the sample to be  
20 analyzed. In the case of leukemias, lymphocytes or leukemic cells will be obtained and appropriately prepared. Similarly, in the case of any metastasized cancer, cells may be drawn from a body fluid such as lymphatic fluid, blood, serum, or a distally infected  
25 organ or exudate thereof. While BAG levels will typically be measured within the cancerous cells of a patient, levels of BAG will also be measured in a body fluid sample (e.g., serum) as a result of BAG having been secreted or otherwise released from cells (e.g., by cell  
30 rupture).

As set forth herein, the invention method for determining the prognosis of a cancer patient comprises: (a) determining the level of BAG gene expression in cancerous tumor cells of a patient, and (b) classifying

the patient as having a either a low or high likelihood of tumor recurrence or spread based on the level of BAG gene expression in the tumor sample or body fluid sample (e.g., serum) of the patient relative to the reference  
5 level.

#### Determining levels of BAG gene expression

Once the patient tissue or cell sample is obtained, prognosis of disease free or overall survival includes determination of the levels of BAG gene  
10 expression or amplification in a cancerous tumor. Measurement of BAG gene expression is performed quantitatively such that the level of gene expression can be determined. The BAG expression level is then used to determine the prognosis of disease-free or overall  
15 survival of a cancer patient based on the correlations provided herein. This is possible because the likelihood of tumor recurrence or spread correlates with the level of BAG expression in tumor cells. For example, it has been found that when the level of BAG expression is high,  
20 the likelihood of metastasis of certain cancers, such as breast cancer, is low. The level of BAG expression may be used as the sole factor in assessing the disease status, or along with the additional factors, including, in the illustrative case of breast cancer, lymph node  
25 status, estrogen receptor status, and the like.

As used herein, "BAG gene" refers to the nucleic acid sequence encoding a protein comprising a BAG domain as set forth in Takayama et al. 1999, Journal of Biological Chemistry 274:781-786, which is incorporated  
30 herein in its entirety. Exemplary BAG proteins include the various isoforms, preferably human, of BAG-1 (including isoforms such as BAG-1N, BAG-1M, and BAG-1L,



see discussion below), BAG-2, BAG-3, BAG-4, BAG-5 proteins, and any other protein which contains a BAG domain and any mutation or partial deletion thereof, including a mutation or partial deletion which results in enhanced or decreased BAG gene expression or in the expression of overactive, underactive, or inactive BAG protein. Other BAG proteins include BAG-1 and BAG-2 proteins from *Caenorhabditis elegans*, and BAG-1A and BAG-1B from *Schizosaccharomyces pombe* (Takayama et al. 1999, supra). Thus, as used herein a BAG protein has a conserved 45-amino acid region near the C-terminus, referred to herein as the BAG domain.

A preferred BAG protein for use herein is human BAG-1. BAG-1 protein was originally identified as a novel regulator of apoptosis by virtue of its ability to bind Bcl-2, a potent blocker of cell death. Since its initial characterization, BAG-1 has been found to interact with not only Bcl-2, but also a number of other proteins which are known to be critical in controlling cell death, including Hsp70/Hsc70, Raf-1, HGF receptor, PDGF receptor, and several steroid hormone receptors.

Previous studies have shown that in both mouse and humans, there is only a single size of BAG-1 mRNA molecules transcribed, but a plurality of sizes of BAG-1 polypeptides are translated (Takayama et al. 1998, Cancer Research 58:3116-3131). In mouse, two isoforms have been identified: the normal length BAG-1 (referred to herein as "BAG-1N"); and a longer BAG-1 polypeptide, or BAG-1L. In human, in addition to the presence of the corresponding BAG-1N and BAG-1L isoforms, a medium length BAG-1 polypeptide, referred to as BAG-1M, is also translated. The cDNA complementary to the BAG-1 mRNA for mouse and human are set forth in U.S. Patent 5,539,094

and in Takayama et al. 1998, supra, (each of which are incorporated herein by reference in their entirety). The polypeptide sequences for the two mouse isoforms BAG-1N and BAG-1L are 219 and 355 amino acids long, respectively  
5 (see Takayama et al. 1998, supra). The polypeptide sequences for human BAG-1N (referred to as BAG-1 in Figure 3C in Takayama et al. 1998, supra), BAG-1M, and BAG-1L are 230, 274 and 345 amino acids in length, respectively.

10 BAG polypeptides, and particularly BAG-1 (especially BAG-1N and BAG-1L), are present in numerous normal human tissues. Both BAG-1N and BAG-1L have been found to be present at abnormal levels in numerous cancers (Takayama et al., 1998, supra; and Yang et al.,  
15 1999, Experimental Cell Research **247**:200-207), including for example: colon cancer, leukemia, lymphoma, breast cancer, prostate cancer, lung cancer, melanoma, ovarian cancer, cervical cancer, and renal cancer. However, a correlation of BAG expression levels with prognosis of  
20 disease-free or overall survival has heretofore been unavailable.

Determination of BAG gene expression or amplification levels may be performed by one or more of the methods known to one of ordinary skill in the art.  
25 For example, BAG amplification or expression levels may be determined by detection of (a) a BAG polypeptide, (b) mRNA encoding a BAG protein, (c) a portion of DNA which constitutes a BAG gene, or (d) any combination thereof.

For example, levels of BAG gene expression can  
30 be detected by measuring levels of BAG protein using agents that bind specifically to a BAG polypeptide. As used herein, the term "agent that binds BAG protein"

refers to any molecule that specifically binds to a BAG protein, including, for example, BAG-1N, BAG-1L, BAG-1M, and/or polypeptide fragments thereof, and thereby detects the level of BAG expression. Such agents are preferably  
5 labeled for detection using methods well known to those of skilled in the art. A variety of agents are contemplated for use herein to specifically detect BAG protein, preferably BAG-1, including proteins known to bind specifically to BAG, antibodies to BAG (such as  
10 described in United States Patent 5,641,866, incorporated herein by reference in its entirety), or peptides which specifically bind BAG. A preferred agent for binding to BAG-1, such as the anti-BAG-1 antibody used herein (See, for example, Takayama et al. 1998, supra, for description  
15 of antibody preparation) binds to all isoforms of BAG-1.

Other, non-antibody proteins, may also be used as "agents." For example, BAG proteins are known to specifically bind numerous proteins, such as Bcl-1, Raf-1, HGF-receptor, PDGF-receptor, Hsp70, Hsc70, steroid  
20 hormone receptors, and the like. As a result, any of these proteins, or active BAG binding fragments thereof, may be used to specifically bind BAG. An exemplary active binding fragment of a protein which binds BAG-1 (and also BAG-2 and BAG-3) is a BAG binding domain of  
25 Hsp70. The ATPase domain of Hsp70 may be expressed in a truncated form, lacking the carboxy-terminal peptide-binding domain. In this form, Hsp70 will not indiscriminantly bind proteins in non-native conformations; however, the ATPase domain of Hsp70 is  
30 still capable of binding BAG-1 (or BAG-2 or BAG-3) protein. Therefore, an actively binding fragment of a protein known to specifically bind BAG may be used as an "agent" which specifically binds BAG protein.

Antibodies, both monoclonal and polyclonal, may be used as specifically binding agents which bind BAG protein or a polypeptide fragment thereof. Also contemplated herein as BAG binding agents are any mutants  
5 of proteins which specifically bind BAG, whether by deletion (as above exemplified), addition (e.g., addition of a GST domain or a GFP domain), or sequence modification (e.g., site-specific mutagenesis), and the like.

10 It is also contemplated herein that one or more of the BAG specific binding agents may be used in a single assay to measure BAG protein levels. For example, a certain protein known to interact with a specific portion of the BAG-1 protein, such as, for example, a  
15 first antibody raised against the N-terminal 60 amino acids of the BAG-1L protein, may be coupled with another specifically binding protein, such as a second antibody raised against a sequence contained in both BAG-1N and BAG-1L. Using these two antibodies in a single assay,  
20 the specific levels of the differently translated BAG-1 polypeptides may be measured by differentially measuring the two antibodies.

Preparation of the agent for use in the detection of BAG protein levels will be carried out using  
25 the methods of one of ordinary skill in the art, such as the methods exemplified in the Current Protocols in Molecular Biology, and in U.S. Patent No. 5,882,864. Similarly, detection of BAG protein levels may be carried out using any of the methods known to one of ordinary  
30 skill in the art including histochemical staining, Western Blot analysis, immunoprecipitation (or the equivalent thereof for non-antibody agents), and the like. In a preferred embodiment of the invention, the

method of detecting BAG protein levels is an immunoassay (such as an ELISA, immuno-PCR, and the like), which includes the use of at least one antibody. Measurement of the polypeptide encoded by a BAG gene may include

5 measurements of fragments of the polypeptide, wherein the fragments arise from transcriptional or translational variants of the gene; or alternatively, differently sized polypeptides arise as a result of post translational modifications including proteolysis of a larger portion

10 of a BAG polypeptide.

An exemplary immuno assay for use in the invention methods for detecting BAG protein levels is an immuno-polymerase chain reaction immuno-PCR assay (described in U.S. Patent 5,665,539, which is

15 incorporated herein in its entirety). Immuno-PCR utilizes an antibody (or other agent which binds BAG) to detect the BAG protein, wherein the antibody (or other agent) is linked to a molecule (typically biotin) which specifically binds a bridging molecule (typically

20 avidin), wherein this bridging molecule is capable of binding a second molecule (typically biotin) attached to a nucleic acid marker. This nucleic acid marker is then amplified using PCR methods. This sensitive detection method is particularly useful when BAG levels are often

25 difficult to detect by other methods, for example, detection of BAG in serum.

Measurement of the polypeptide encoded by a BAG gene may further be carried out to specifically measure:

(a) the level of BAG produced in the entire cell, (b) the

30 level of BAG produced in the cytosol, (c) the level of BAG produced in the nucleus, (d) level of BAG present in cell-free extract (e.g., serum), and (e) any combination thereof. Exemplary methods which can be used in such

measurements include *in situ* methods such as histochemical staining, particularly differential staining between the cytosol and the nucleus, and *in vitro* methods such as Western blot analysis of nuclear  
5 extracts, cytosolic extracts, or serum.

Detection of levels of mRNA encoding BAG may also serve as an indicator of BAG expression. The methods used to detect mRNA levels will include the detection of hybridization or amplification with the mRNA  
10 encoding BAG. This detection may be carried out by analysis of mRNA either *in vitro* or *in situ* (e.g., in a tissue sample) using one of the methods known to one of ordinary skill in the art as exemplified in the Current Protocols in Molecular Biology (John Wiley & Sons, 1999);  
15 in U.S. Patent No. 5,882,864; and the like. A BAG mRNA detected will be any RNA transcript of a BAG gene, or fragment thereof.

Detection of the DNA encoding BAG may also be used as an indicator of BAG expression. A plurality of  
20 changes from wild type in the portion of DNA which constitutes a BAG gene may influence levels of gene expression. For example, gene amplification will provide more copies of a BAG gene within each cell, thereby facilitating the manufacture of an increased number of  
25 mRNA molecules encoding BAG, which may result in an increased level of BAG protein within the cell. In another example, gene translocation or partial gene deletion may have an effect on the rate of gene expression by, for example, decreasing the ability of a  
30 repressor protein to repress BAG transcription, resulting in higher levels of BAG protein within the cell. Detection of the portion of DNA which constitutes a BAG gene may have application by indicating the occurrence of

gene amplification, translocation, mutation, partial deletion, or other modification of the copy number, sequence, location, or accessibility of a BAG gene which results in abnormal levels of expression of a BAG gene.

5                   Detection of the DNA constituting a BAG gene may take place by a variety of methods known to those of skill in the art. Such methods will typically include the detection of hybridization to the DNA constituting a BAG gene, or amplification of the DNA constituting a BAG  
10 gene. This method may be carried out by analysis of cellular DNA either *in vitro* or *in situ*. Numerous methods for carrying out this detection are known to those of ordinary skill in the art, as exemplified in the Current Protocols in Molecular Biology, and in U.S.  
15 Patent No. 5,882,864, which is incorporated herein in its entirety.

#### Classifying the patient

The classification of particular patients requires comparing the level of BAG gene expression in  
20 the tumor cells of a patient to a reference level (also referred to as a basal level). For example, after measuring the BAG expression level of the cells in a cancerous tumor of a patient, the measured level is compared to a reference level. This reference level is a  
25 level of expression of BAG used to evaluate the level of expression of BAG in cancerous cells of a patient. Specifically, when the level of BAG expression in the cancerous cells of a patient are higher than the  
reference level, the cells will be considered to have a  
30 high level of expression, or overproduction, of BAG. Conversely, when the level of BAG expression in the cancerous cells of a patient are lower than the reference

level, the cells will be considered to have a low level of expression, or underproduction, of BAG.

As used herein, the terms "high level" or "overproduction" of BAG gene expression is related to a level of BAG gene expression above a determined basal level and is likely different for each cancer type. Thus, in accordance with the present invention a reference or basal level of BAG gene expression in a particular cancer cell type is identified as a "cutoff" value, above which there is a significant correlation between the presence of BAG gene expression and increased or decreased tumor recurrence or spread. Those of skill in the art will recognize that some "cutoff" values are not sharp in that clinical correlations are still significant over a range of values on either side of the cutoff; however, it is possible to select an optimal cutoff value (e.g. varying H-scores, and the like) of BAG gene expression for each cancer cell type. It is understood that improvements in optimal cutoff values could be determined, depending on the sophistication of statistical methods used and on the number and source of samples used to determine reference or basal values for the different cancer cell types.

Such "overproduction" is not typically calculated in terms of absolute BAG gene expression or protein levels, but is determined using relative measurements. These relative measurements are illustrated for quantitation purposes with an "internal standard;" however, it will be appreciated that other standards or methods of determination may be used, such as comparison with external standards, BAG mRNA measurements, measurement of the DNA constituting a BAG



gene, absolute values of the protein or mRNA or DNA levels, and the like.

The reference level may be determined by a plurality of methods, provided that the resulting  
5 reference level accurately provides a level of BAG expression above which exists a first group of patients having a different risk of tumor recurrence or spread than that of a second group of patients having BAG expression levels below the reference level. The  
10 reference level may be determined by, for example, measuring level of expression of BAG in non-tumorous cancer cells from the same tissue as the tissue of the cancer cells to be tested. The reference level may also be a level of BAG expression of *in vitro* cultured cells  
15 which may or may not have been manipulated to simulate tumor cells, or may have been manipulated in any other manner which yields expression levels which accurately determine the reference level.

It is important to recognize that reference  
20 levels are not necessarily the levels of BAG expression found in cultured cell lines used to provide internal standards. Rather, these may be reference level amounts of BAG gene expression (e.g., BAG protein, BAG mRNA, and the like) that occur in tumor cells. It is, for example,  
25 possible that a high level of BAG gene expression in a tumor sample will have a relatively lower expression level than the corresponding BAG protein expression level in an internal standard.

The reference level may also be determined by  
30 comparison of BAG expression levels in populations of patients having the same cancer. This may be accomplished by histogram analysis, in which the entire

cohort of patients tested are graphically presented, wherein a first axis represents the level of BAG expression, and a second axis represents the number of patients in the cohort whose tumor cells express BAG at a given level. Two or more separate groups of patients may be determined by identification of subsets populations of the cohort which have the same or similar expression levels of BAG. Determination of the reference level may then be made based on an expression level which best distinguishes these separate groups.

Verification that the reference level distinguishes the likelihood of tumor recurrence or spread in cancer patients expressing below-reference levels of BAG versus cancer patients expressing above-reference levels of BAG is carried out using single variable or multi-variable analysis. These methods determine the likelihood of a correlation between one or more variables and a given outcome. In the specific case, the methods will determine the likelihood of a correlation between BAG expression levels (or BAG expression levels coupled with another variable) and disease-free or overall survival of cancer patients. Any one of a plurality of methods well known to those of ordinary skill in the art for carrying out these analyses may be used. Examples of single variable analysis is the Kaplan-Meir method or the log-rank test. An example of multi-variable analysis is the Cox proportional-hazards regression model.

Population-based determination of reference levels (e.g., histogram analysis) is carried out using a cohort of patients sufficient in size in order to determine two or more separate groups of patients having different BAG expression levels. Typically, such a

cohort comprises at least 25 patients, preferably 50 patients, more preferably 75 patients, and yet more preferably at least 100 patients. Similarly, verification of determined reference levels will also  
5 comprise at least 25 patients, preferably 50 patients, more preferably 75 patients, and yet more preferably at least 100 patients.

The reference level may be a single number, equally applicable to every patient, or the reference  
10 level may vary, according to specific subpopulations of patients. For example, men might have a different reference level than women for the same cancer. Furthermore, the reference level might be some level determined for each patient individually. For example,  
15 the reference level might be a certain ratio of BAG expression in the tumor cells of a patient relative to BAG expression in non-tumor cells within the same patient. Thus the reference level for each patient may be proscribed by a reference ratio of BAG expression,  
20 wherein the reference ratio may be determined by any of the methods for determining the reference levels described above.

Further, while the reference level described above discusses a number which separates two groups of  
25 patients, it is within the scope of the invention that numerous reference values might exist which separate a plurality of populations. For example, two reference values may separate a first group of patients with high levels of BAG expression from a second group of patients  
30 with intermediate levels of BAG expression, and from a third group of patients with low levels of BAG expression. The number of different reference levels may be sufficient to proscribe a curve, such as a continuous

line, which describes the likelihood of disease-free or overall survival in a patient as a function of BAG expression level in that patient. Such a curve will constitute a "continuous" BAG reference level, where the likelihood of disease free or overall survival in a patient is portionional to the level of BAG expression level in that patient.

The reference level can also represent the level of BAG protein in one or more compartments of the cell. Typically, the reference level will represent the level of BAG protein in (a) the whole cell, (b) the nucleus, or (c) the cytosol. This level will be useful when cell compartmentalization of BAG protein correlates with the risk of tumor recurrence or spread of a certain cancer. For example, it has been observed that the level of BAG protein is higher in the cytosol of patients with low risk of breast cancer recurrence or spread than the cytosolic BAG protein level of patients with high risk of breast cancer recurrence or spread, despite the fact that the level of BAG expression in the nucleus can be roughly equivalent. Similarly, the reference level may be a ratio of levels of BAG protein in the different compartments (e.g., the ratio of nuclear BAG protein to whole cell BAG protein, or the ratio of nuclear BAG protein to cytosolic BAG protein).

It is also contemplated herein that the reference level can represent the level of expression of a single form of BAG (e.g., BAG-1N, BAG-1M, BAG-1L, BAG-2, BAG-3, BAG-4, OR BAG-5). This reference level will be useful when a single translated form of BAG correlates with the risk of tumor recurrence or spread of a certain cancer. For example, it may be observed that the level of BAG-1L expression is higher in patients with

low risk of lung cancer recurrence or spread than the level of BAG-1L expression in patients with high risk of lung cancer recurrence or spread, despite the fact that the level of total BAG-1 expression (i.e., the sum of BAG-1N, BAG-1M, or BAG-1L expression levels) is the same for all patients. Similarly, the reference level may be a ratio of levels of expression for different forms of BAG (e.g., the ratio of BAG-1N to BAG-1L, the ratio of BAG-2 to BAG-3, and the like).

10           The reference level of BAG expression may further be used in conjunction with another variable found to be a statistically significant indicator of the likelihood of disease-free or overall survival for a specific cancer. Such indicators include the presence or  
15 levels of biomarkers of such as other proteins (e.g., ras, Bcl-2, and the like), or may be clinical or pathological indicators (e.g., age, tumor size, tumor histology, clinical stage, and the like). For example, clinical stage of the cancer is also be a statistically  
20 significant indicator of disease-free or overall survival (in addition to BAG expression level), wherein the reference level of BAG expression may vary according to the clinical stage of the cancer. For example, levels of BAG expression, preferably high levels of BAG-1, in  
25 conjunction with clinical stage I of a cancer for a given patient, are particularly preferred indicators for increased likelihood of disease free or overall survival.

Hence, the reference level of BAG expression may vary as a function of another statistically significant indicator  
30 of disease-free or overall survival for a specific cancer.

Those of skill in the art will recognize that it is also possible to measure levels of BAG proteins in

body fluid, such as serum. Tumors are known to readily shed cells which, after release into the bloodstream, may burst due to cell fragility. For example, it is contemplated herein that overexpression of BAG-1 observed in approximately 2/3 of breast cancer patients results in increased secretion and/or release of BAG-1 protein into serum. Thus, detection of any BAG levels, preferably high BAG-1 levels, present in body fluid (e.g., serum) is contemplated for use in the invention methods to determine a prognosis of disease free or overall survival in a manner analogous to that demonstrated with the tissue samples. Very small quantities of BAG can be measured in body fluid, for example, using anti-BAG antibodies in immuno-PCR methods as described herein.

Accordingly, it is contemplated herein that the reference levels may represent the level of BAG present in a body fluid sample, such as serum. Invention methods that measure the level of circulating BAG (i.e., the level of BAG in blood or serum), preferably BAG-1, will have a particularly preferred application to early diagnosis and screening, and early determination of risk of cancer recurrence or spread, for patients with abnormal levels of BAG (e.g., high levels) in their serum.

After the levels of expression of BAG in the tumor cells of a patient have been determined and compared to a reference level, the patient is then classified into a group having a certain likelihood of disease free or overall survival. Then the likelihood of disease-free or overall survival for the patient is assessed based on the likelihood of disease-free or overall survival for patients in that group. For example, the tumor cells of a specific breast cancer

patient may be determined to have high levels of BAG expression relative to a reference level. This patient would then be classified into a group of patients having high levels of BAG expression. Since, in accordance with the present invention, it has been discovered that there is an increased likelihood of disease-free or overall survival for the group of patients expressing high levels of BAG-1 in breast cancer cells (relative to those expressing low levels of BAG-1 in breast cancer cells), the specific breast cancer patient would be considered to have an increased likelihood of disease free or overall survival.

In another embodiment of the present invention, a method is provided for prognosis of disease-free or overall survival of individuals having a cancer tumor. In particular, the method comprises determining whether BAG protein is overproduced in a sample of such a tumor, wherein such an overproduction correlates positively with disease-free or overall survival. Thus, patients who produce high levels of BAG protein have an increased likelihood of survival relative to patients producing low levels of BAG protein.

Another embodiment of the invention provides a method for screening a cancer patient to determine the risk of tumor metastasis. The method comprises determining the level of amplification or expression of a BAG gene in a cancerous tissue sample from the patient. A patient found to have high levels of amplification or expression of the BAG gene, relative to a reference level, is classified as being less likely to suffer tumor metastasis or having a increased chance of survival.

As used herein, the term "metastasis" refers to the growth of a cancerous tumor in an organ or body part, which is not directly connected to the organ of the original cancerous tumor. Metastasis will be understood to include micrometastasis, which is the presence of an undetectable amount of cancerous cells in an organ or body part which is not directly connected to the organ of the original cancerous tumor. Therefore, the present invention contemplates a method of determining the risk of further growth of one or more cancerous tumors in an organ or body part which is not directly connected to the organ of the original cancerous tumor.

In yet another embodiment of the invention, methods are provided for the determination of levels of BAG expression in cancer patients at an early stage of tumor development. As used herein, the term "stage", when applied to tumor development, refers to the degree of progression of a tumor. Various stages of tumor development are well known to those of skill in the art, as exemplified in Markman 1997, Basic Cancer Medicine. Stages of different cancers are defined according to different criteria, typically using the Tumor-Node-Metastasis (TNM) system. For example, stage I of breast cancer requires no lymph node involvement, and stage II of breast cancer involves either no lymph node involvement and a large primary tumor, or initial lymph node involvement and a small primary tumor (see Markman, supra, pages 35 and 36). Similar descriptions of the various clinical stages can be found in Markman, supra, for lung cancer (pages 54 to 55), and prostate cancer (pages 64 to 65), colon cancer (pages 78 to 79) and ovarian cancer (page 38 to 39). Early stages of tumor development shall be understood to refer to stages in tumor development in which the tumor has detectably



spread no further than the lymph nodes local to the organ of the primary tumor. Typically, early stages will be considered to be stages I and II. As used herein, the phrase, "prior to lymph node involvement" refers to the  
5 detectable presence of cancer cells in the organ of the primary tumor, but the lack of a detectable presence of cancer cells in any lymph nodes, including the lymph nodes closest to the organ of the primary tumor.

The predictive value of the method of the  
10 invention will be particularly effective in the case of patients in the early stages of cancer. This is because the method of the invention is advantageously effective in determining the risk of metastasis in patients who demonstrate no measurable metastasis at the time of  
15 examination. One of ordinary skill in the art would appreciate that the prognostic indicators of survival for cancer patients suffering from stage I cancer may be different from those for cancer patients suffering from stage IV cancer. For example, prognosis for stage I  
20 cancer patients may be oriented toward the likelihood of continued growth and/or metastasis of the cancer, whereas prognosis for stage IV cancer patients may be oriented toward the likely effectiveness of therapeutic methods for treating the cancer.

25 In another embodiment of the invention, a kit is provided to determine the levels of BAG expression in the cancerous tumor cells of the patient. Such a kit will comprise a reagent for detecting either the DNA encoding BAG, the mRNA encoding BAG, the BAG polypeptide,  
30 or any combination thereof. The reagent will comprise one or more molecules capable of specifically binding a nucleic acid sequence (DNA or RNA) encoding BAG, or the BAG polypeptide.

The kit may comprise one or more nucleic acid reagents for the detection of either DNA encoding BAG, mRNA encoding BAG, or both. The one or more nucleic acid reagents may be used for hybridization or amplification with the DNA and/or mRNA encoding BAG. The kit may comprise one or more pairs of primers for amplifying the DNA and/or mRNA encoding BAG. The kit may further comprise samples of total mRNA derived from tissue of various physiological states, such as normal, and metastatically progressive tumor, for example, to be used as controls. The kit may also comprise buffers, nucleotide bases, and other compositions to be used in hybridization and/or amplification reactions. Each solution or composition may be contained in a vial or bottle and all vials held in close confinement in a box for commercial sale. Another embodiment of the present invention encompasses a kit for use in detecting the DNA and/or mRNA encoding BAG in cancer cells in a biological sample comprising oligonucleotide probes effective to bind with high affinity to DNA and/or mRNA encoding BAG *in vitro* or *in situ* and containers for each of these probes.

In a further embodiment, the invention encompasses a kit for use in determining the level of BAG expression in a biological sample comprising one or more agents, such as, for example, one or more antibodies, specific for one or more BAG polypeptides. In one particular embodiment, the kit will comprise one or more agents and one or more nucleic acid markers wherein the agents and nucleic acid markers are modified in a fashion appropriate for carrying out immuno-polymerase chain reaction assays.

Another embodiment of the invention provides a method for determining the proper course of treatment for a patient suffering from cancer. This method comprises determining the level of expression of a BAG gene in  
5 cancerous tissues from a patient. Then, a first group of patients is identified as having low levels of expression of a BAG gene in the cells. This first group of patients may require treatment proper for patients having a lesser chance of survival or decreased time to tumor recurrence  
10 or spread. The method further comprises identifying a second group of patients as having high levels of expression of a BAG gene in the cells. This second group of patients may require treatment proper for patients having a greater chance of survival and being less likely  
15 to suffer tumor recurrence or spread.

Appropriate treatments for patients having greater or lesser chances of survival will be determined, with proper consideration of other factors, by one of ordinary skill in the art according to the available  
20 therapeutic methods. As used herein, "course of treatment" shall be understood to represent the treatment (e.g., surgery, chemotherapy, radiation, and the like) of a patient after diagnosis for cancer, and the span of time during which the patient is treated. Hence, a point  
25 in time considered to be "during the course of treatment" shall represent any time between the initiation of the course of treatment and the termination of the course of treatment.

In a further embodiment of the invention, a  
30 method is provided for monitoring the effectiveness of a course of treatment for a patient suffering from cancer. This method comprises:

(a) determining a first BAG gene expression level in a cancerous tissue sample or a body fluid sample from said patient prior to said treatment; and

- 5 (b) subsequently determining a second BAG gene expression level in a cancerous tissue sample or a body fluid sample from said patient during said treatment.

Comparison of said first BAG expression level with said  
10 second BAG expression level will then indicate the effectiveness of said treatment.

As used in the context of a course of treatment, "effectiveness" refers to the ability of the course of treatment to decrease the risk of tumor  
15 recurrence or spread and therefore to increase the likelihood of disease-free or overall survival of the patient. This method will have particular utility when the level of BAG expression in the tumor cells of a patient is abnormal compared to the level of BAG  
20 expression in the non-tumor cells of the patient. Comparison of the first and second BAG expression levels will thereby serve to indicate whether BAG expression level is returning to that of non-tumor cells, implying a more effective course of treatment, or whether BAG  
25 expression level is remaining abnormal or increasing in abnormality, implying a less effective course of treatment. Levels of BAG expression may be determined using a plurality of samples from the patient, as described herein. A preferable sample form for this  
30 embodiment shall be a body fluid sample, such as serum sample, an exudate sample, and the like.

This embodiment of the invention is particularly useful when combined with the method of

determining the risk of tumor recurrence or spread in a cancer patient, and thereby determining the proper course of treatment in a cancer patient. Specifically, the proper course of treatment of a cancer patient may be  
5 determined by determining the level of BAG expression in a sample from a patient, then classifying the patient's likelihood of disease-free or overall survival according to the level of BAG expression. The course of treatment may then be monitored, according to the present  
10 embodiment of the invention, on one or more occasions to determine the effectiveness of the course of treatment.

In a further embodiment of this invention, a method is provided for determining a prognosis of disease free or overall survival in a patient suffering from  
15 cancer. This method comprises:

- (a) determining a BAG activity level in a cancerous tissue sample or body fluid sample from said patient; and
- (b) classifying said patient as belonging  
20 to either a first or second group of patients, wherein said first group of patients having high levels of BAG activity is classified as having a different likelihood of suffering tumor recurrence or spread than said second  
25 group of patients having low levels of BAG activity.

As used herein, "BAG activity level" or level of "BAG activity" refers to the level of active, uninhibited BAG polypeptides present in tumor cells or  
30 body fluid, and the degree of activity of these polypeptides. Hence, level of activity shall be influenced by a plurality of factors including: levels of BAG, presence of less active or more active forms

(including isoforms) of BAG, presence of less active or more active mutants of BAG, presence of proteins or other molecules which increase BAG activity, presence of proteins or other molecules which decrease BAG activity.

5 For example, levels of an antagonist to BAG, such as Hip (an antagonist to BAG-1, see for example Hohfeld and Jentsch 1997, EMBO J 16:6029-6216), will be understood to commensurately lower BAG activity even if BAG protein levels remain unchanged. Determination of BAG activity

10 shall therefore be carried out by a plurality of methods, including: assay of biological activity of BAG (such as ability to prevent cell death or other apoptotic assays, see, for example, United States Patent 5,550,019), assay of BAG protein levels, assay of the mRNA encoding a BAG

15 protein, assay of the DNA which constitutes a BAG gene, assay of proteins (or the mRNA or DNA encoding the proteins) or other molecules which increase or decrease BAG activity, and any combination thereof.

All U.S. patents and all publications mentioned

20 herein are incorporated in their entirety by reference thereto. The invention will now be described in greater detail by reference to the following non-limiting example.

#### EXAMPLES

25 1.0 BAG1 IMMUNOSTAINING PREDICTS LONGER SURVIVAL IN BREAST CANCER PATIENTS WITH TUMOR-NEGATIVE LYMPH-NODES.

The role of BAG1 (also known as RAP46 and HAP-1) immunostaining for prognostic evaluation of women with

30 breast cancer was assessed for patients with negative lymph-node biopsies (i.e. no evidence of tumor in axillary nodes which have been surgically removed for

histological examination) by analysis of a cohort of women with stage-I disease. This example illustrates the determination of the reference level of BAG-1 expression in breast cancer patients, and evaluation of the accuracy  
5 of the reference level in predicting disease-free or overall survival of separate groups having different BAG-1 expression levels.

A retrospective correlative analysis was performed of BAG-1 using a monoclonal antibody capable of  
10 detecting BAG-1N, BAG-1M and BAG-1L (see Takayama et al., 1998, supra). Estrogen Receptor (ER), Progesterone Receptor (PR), HER2/Neu, p53, Bcl-2, Bax, which have all been implicated in breast cancer formation, were also assayed. Immunohistochemical methods were carried out on  
15 archival paraffin blocks derived from 116 women with early-stage (stage I: n = 73, 63%; and stage-II: n = 43, 37%) breast cancer who were treated with lumpectomy followed by radiation therapy to the intact breast using a median dose of 48 Grays (Gy) followed by an electron  
20 boost to the lumpectomy site to yield a total median dose of 64 Gy. There were 17/116 (15%) patients treated with adjuvant systemic chemotherapy and 20/116 (17%) patients treated with tamoxifen therapy. The patients had a median follow-up of 12.4 years, with a minimum follow-up  
25 of 4 years (Table 1).

**Table 1. Characteristics of breast cancer cases**

DATA	No.	%
Number of patients	116	NA
Mean age (yrs.)	55	NA
Infiltrating ductal cancer	103	(89%)
Infiltrating lobular cancer	9	(8%)
Infiltrating medullary cancer	4	(3%)

	Median follow-up (yrs.)	12.4	NA
	Stage I/II	116	(100%)
	Stage I	73	(63%)
	Stage II	43	(37%)
5	Mean pathologic size (cm)	1.8	NA
	Axillary dissection	62	(53%)
	Positive lymph nodes	13	(11%)
	Estrogen receptor positive	49	(42%)
	Adjuvant chemotherapy	17	(15%)
10	Adjuvant tamoxifen	20	(17%)
	Metastatic Disease	35	(30%)

The characteristics of patients used for this study are summarized: number (left column); percentage (right column). Metastatic disease indicates the number (and percentage) of patients who developed clinically detectable metastatic disease after diagnosis and treatment.

Immunostaining was carried out by colorimetric antibody detection using diaminobenzidine (brown) followed by hematoxylin (blue) counterstaining of nuclei. Immunostaining of the invasive component of breast cancers was scored according to intensity (0-4, wherein 0 is no staining and 4 is the most intense staining) and percentage of immunopositive cells (0-100%, for a minimum of 200 cells), evaluating the entire tissue-section, with the pathologist blinded to clinical details. Histo-staining (H)-scores (0-400) were obtained by determining the product of intensity (0-4 scale) and percentage (0-100%). To set cut-offs for dichotomization of data into groups having high and low levels of expression, the H-score data for the entire data-set were displayed as dot-histograms with H-score on the x-axis and the number of patient samples having a given H-score on the y-axis. An H-score  $\geq 150$  was determined by this approach to be appropriate for use as a cut-off for high levels of BAG-1



expression. H-score data were displayed as histograms and dichotomized into high versus low expression level groups using optimized cut-offs for BAG-1 (H-score $\geq$ 150), Bcl-2 (H-score $\geq$ 180), and Bax (H-score $\geq$ 140).

- 5 Immunoscoring for ER, PR, p53, and HER2/Neu was performed by established criteria (King et al., 1985, Cancer Research **45**: 293-296).

BAG-1 is known to be present in the nuclei of some types of cells and nuclear immunostaining is normal  
10 for breast epithelium, whereas strong cytosolic immunostaining is abnormal here (Takayama et al. 1998, supra). This phenomenon was confirmed in the present example: compared to normal breast epithelium (NBE) cells, which were often present along with tumor cells in  
15 the same tissue-sections, cytosolic immunostaining for BAG-1 was clearly upregulated within the invasive breast cancer cells, with elevated levels of protein observed for 77/116 (66%) or roughly two-thirds of early-stage breast cancers compared with 9/83 (11%) of NBE ( $p < 0.001$ ).

20 Some of the same tumor specimens also contained histologically evident ductal carcinomas in situ (DCIS); high levels of BAG-1 nuclear immunostaining were found in 9/12 (75%) and 6/12 (50%) sections had high levels of cytoplasmic BAG-1 protein levels in DCIS specimens,  
25 suggesting that upregulation of BAG-1 can occur as a relatively early event in tumorigenesis and the translocation of protein from the nucleus to the cytoplasm may be important in cellular transformation.

Immunostaining data were correlated with  
30 distant metastasis-free survival (DMFS) and overall survival (OS). Kaplan-Meier analysis revealed that elevated levels of BAG-1 were significantly associated (i.e.,  $p \leq 0.05$ ) with longer DMFS ( $p < 0.001$ ) and OS

( $p < 0.001$ ) (Figure 1). The group of patients having high BAG-1 protein levels (BAG-1 positive) experienced better 10-year DMFS than the group of patients having low (BAG-1 negative) BAG-1 protein levels (90% high group vs. 40% low group) and OS (84% high group vs. 40% low group). Among the other biomarkers evaluated, only Bcl-2 was significant in univariate analysis as a predictor of longer DMFS ( $p < 0.001$ ) and OS ( $p < 0.001$ ). ER, PR, HER2/Neu, p53, and Bax were all insignificant in predicting survival for this cohort of patients. Among clinical and pathological variables (e.g., age; tumor size; stage; tumor histology), only clinical stage I versus clinical stage II was significant in univariate analysis for predicting survival.

In multivariate models using Cox-regression analysis with variables including BAG-1, Bcl-2, Bax, p53, ER, PR, HER2/Neu, age and clinical stage, only BAG-1 retained statistical significance as a predictor of DMFS ( $p = 0.008$ ) and OS ( $p = 0.02$ ). All other biomarkers failed to reach clear statistical significance and clinical stage (stage I versus stage II) was significant only for DMFS ( $p = 0.029$ ) but not OS. Thus, patients whose tumors contain high levels of cytosolic BAG-1 protein are more likely to enjoy long-term survival and freedom from tumor recurrence or spread and distant metastases, compared to those with tumors containing low levels of cytosolic BAG-1. These results demonstrate that BAG represents a novel and independent prognostic factor which is associated with favorable outcome in patients with early-stage breast cancer.

2.0 BAG1 IMMUNOSTAINING PREDICTS LONGER SURVIVAL IN  
BREAST CANCER PATIENTS WITH TUMOR-POSITIVE LYMPH-NODES.

To address the role of BAG1 immunostaining as a prognostic factor for women with node-positive disease,  
5 an immunohistochemical evaluation using the anti-BAG1 monoclonal antibody described in Example 1.0 was performed of tumor specimens derived from a cohort of 342 patients with node-positive breast cancer, 179 of whom were treated with surgery alone and 209 of whom underwent  
10 surgical resection followed by 12 monthly cycles of cyclophosphamide, methotrexate, fluorouracil ("CMF") adjuvant therapy. The percentage of tumor cells with cytosolic BAG1 immunopositivity was estimated by light-microscopic evaluation, and the data were gathered into  
15 quartiles, representing 0-10%, 11-50%, 51-80%, and >80% immunopositive tumor cells.

Correlations of the data with relapse-free survival (RFS) and cause-specific survival (CSS) by the Kaplan-Meyer method revealed that the first 3 quartiles  
20 behaved similarly, while the fourth quartile (>80% BAG1 immunopositive tumor cells) was significantly different. Examining the entire cohort of 342 patients, higher levels of BAG1 immunostaining (>80% positive) were associated with longer RFS and CSS, as determined by  
25 univariate analysis ( $p = 0.05$  for both RFS and CSS) (see Figures 2 and 3). For example, the percentage of patients not dead due to cancer was 42% among patients whose tumors contained >80% BAG1 immunopositive malignant cells compared to 34% for patients whose tumors contained  
30 lower percentages of BAG1 positive cells (Table 2). Whether the patients did or did not receive adjuvant CMF therapy, whether their tumors expressed or did not express Estrogen Receptors (ER), and the number of positive nodes ( $>3$  vs  $<3$ ) were also of prognostic

significance. Other variables were not predictive of outcome, including menopausal status, tumor size (< 2 cm versus > 2 cm), or other biomarkers such as Bcl-2 (Table 2) and p53.

5

**TABLE 2**

Results at 20 yrs

Total Series (Univariate analysis)

	%RFS	%P	%CCS	%P
BAG1-	26	0.05	34	0.05
BAG1+	29		42	
Control	22	0.003	28	0.01
CMF	31		43	
Premenop	27	0.67	39	0.42
Postmenop	27		34	
T $\leq$ 2cm	29	0.20	37	0.38
T>2cm	25		36	
N+1-3	31	0.0002	41	0.0007
N+>3	19		28	
ER+	26	0.58	38	0.02
ER-	29		34	
BCL2+	26	0.94	37	0.26
BCL2-	34		37	

Legends: RFS (relapse-free survival)

CCS (cause specific survival)

When the 179 women treated with surgery alone were evaluated separately, again higher levels of BAG1 immunopositivity were associated with longer RFS and CSS ( $p = 0.027$  for RFS;  $p = 0.039$  for CSS) in univariate analysis (Table 3). For example, 28% of patients whose tumors exhibited high BAG1 immunostaining were relapse-free at 20 years after initial diagnosis and therapy,

compared to only 19% of patients whose tumors had low BAG1 expression (Table 3). BAG1 immunostaining data, however, were not significantly correlated with survival when the 209 patients who received adjuvant chemotherapy were examined separately, suggesting that BAG1 loses its prognostic significance in this setting.

**TABLE 3**

Results at 20 yrs

Control (Surgery only; Univariate analysis)

	%RFS	%P	%CCS	%P
10 BAG1-	19	0.027	23	0.039
BAG1+	28		38	
Premenop	20	0.23	25	0.25
Postmenop	24		32	
T $\leq$ 2cm	24	0.14	28	0.46
15 T>2cm	21		29	
N+1-3	25	0.009	30	0.04
N+>3	17		27	
ER+	20	0.70	30	0.038
ER-	27		27	
20 BCL2+	21	0.95	28	0.76
BCL2-	29		33	

Multivariate analysis (Table 4), using a Cox-regression analysis, also demonstrated a significant correlation of higher levels of BAG1 immunostaining with longer CSS when all 342 patients were considered together (p = 0.046). BAG1 was also significantly associated with longer CSS (p = 0.022) when patients treated with surgery alone (179) were evaluated, but not among the

subgroup of patients who received adjuvant therapy. Thus, BAG1 is an independent predictor of RFS and CSS in women with node-positive breast cancer who do not receive adjuvant chemotherapy after surgery, even when other  
 5 variables are considered, including extent of nodal involvement, menopausal status, and ER status.

**TABLE 4**

BAG1 CASE SERIES  
 RESULTS AT 20 YRS

10 COX REGRESSION ANALYSIS

Total Series		HR (95% CI)	P
RFS	Treatment	0.66(0.51-0.86)	0.0021
	Nodal extent	1.65(1.25-2.17)	0.0003
	BAG1	1.30(0.98-1.73)	0.064
CCS	Treatment	0.67(0.51-0.90)	0.0068
	Nodal extent	1.61(1.20-2.16)	0.0015
	BAG1	1.37(1.01-1.87)	0.046
	ER	0.67(0.49-0.91)	0.011
CONTROL (Surgery Only)			
15 RFS	Nodal extent	1.59(1.05-2.39)	0.028
	BAG1	1.44(0.96-2.17)	0.079
CCS	BAG1	1.68(1.08-2.63)	0.022
	ER	0.55(0.35-0.86)	0.008
CMF			
RFS	Nodal extent	1.77(1.23-2.56)	0.0023
CCS	Nodal extent	1.86(1.24-1.78)	0.0025
	Menopause	1.54(1.01-2.29)	0.055

### 3.0 IMMUNOHISTOCHEMICAL ANALYSIS OF BAG1 IN PROSTATE CANCER.

#### Pathological Elevations in BAG1L in Prostate Cancers.

Immunohistochemical methods were used to  
5 evaluate the expression of the BAG1N (cytosolic) and  
BAG1L (nuclear) proteins in primary and metastatic  
prostate cancer specimens. Previously it was determined  
that BAG1N is cytosolic while BAG1L is nuclear (BAG1N is  
referred to as BAG-1 in Takayama et al. 1998, Cancer Res.  
10 58:3116-3131) and (Packham et al. 1997, Biochem. J.  
328:807-813). Using anti-BAG1 monoclonal antibodies  
(Takayama et al. 1998, supra), immunohistochemical  
methods and archival paraffin-embedded prostate cancer  
specimens were used to evaluate the expression of the  
15 nuclear (BAG1L) and cytosolic (BAG1N) proteins in over  
800 cases of prostate cancer. Comparisons were made with  
BAG1 immunostaining results in normal prostate and benign  
prostatic hypertrophy. Tissue microarray technology was  
exploited for much of this analysis, permitting the  
20 analysis large numbers of tumor specimens (Kononen et al.  
1998, Nature Med. 4:844-847).

Compared to normal prostate, cytosolic BAG1N  
immunostaining was elevated in 746 of 876 (85%) of  
prostate cancers. Nuclear BAG1 (BAG1L) immunostaining  
25 was inappropriately increased in 171 of 676 (25%) of  
prostate cancers, compared to normal prostate gland  
epithelium. Clinical follow-up data or other types of  
laboratory information were available for some of these  
patients, demonstrating a variety of correlations of BAG1  
30 expression with more aggressive tumor phenotypes. For  
example, in a cohort of 62 patients with early-stage  
(T1,T2) disease and low Gleason grade (gr 2-6), higher

percentages of BAG1 immunopositive tumor cells were associated with higher PSA levels prior to radiation therapy ( $p = 0.05$ ), and with a higher incidence of distant metastases after therapy ( $p = 0.05$ ). Higher intensity

5 BAG1 immunostaining was also associated with a higher incidence of metastatic relapse after radiation therapy ( $p < 0.0001$ ). In addition, immunohistochemical analysis of 722 prostate cancer specimens in a microarray format

10 in tumors ( $n = 722$ ) compared to normal prostate ( $n = 54$ ): mean + SE:  $41 \pm 3\%$  normal versus  $78 \pm 1\%$  cancer ( $p < 0.0001$ ). An association was also identified between higher percentages of BAG1 immunopositive tumor cells and

15 locally advanced disease ( $p = 0.05$ ) ( $n = 625$  patients) and with hormone refractory disease ( $p < 0.001$ ) ( $n = 263$  patients).

Higher percentages of tumor cells with nuclear BAG1-immunostaining (BAG1L) as well as higher intensity nuclear BAG1L (BAG1L intensity) staining were also

20 associated with hormone-refractory disease:  $p < 0.001$  and  $p < 0.0001$ , respectively ( $n = 263$ ). Higher intensity BAG1 nuclear immunostaining was also correlated with hormone-refractory (HR) disease in a cohort of 92 prostate cancer patients with locally-advanced disease who were treated

25 with anti-androgen therapy prior to surgery (50% vs 9% HR;  $p < 0.001$ ).

From these observations, three conclusions can be reached. First, tumor-specific increases in cytosolic BAG1 and nuclear BAG1L levels commonly occur in prostate

30 cancers. Second, immunohistochemical analysis of BAG1N (cytosolic) and BAG1L (nuclear) expression provides prognostic information about prostate cancer patients, including information about progression to hormone-refractory disease. Third, unlike the situation with



breast cancer, higher levels of cytosolic BAG1N expression are associated with unfavorable prognosis rather than favorable prognosis.

Although the invention has been described with  
5 reference to the disclosed embodiments, it should be understood that various modifications can be made without departing from the spirit of the invention. Accordingly, the invention is limited only by the following claims.

We Claim:

1. A method for determining a prognosis of disease free or overall survival in a patient suffering from cancer, said method comprising:

5 (a) determining a BAG gene expression level in a cancerous tissue sample or body fluid from said patient; and

(b) classifying said patient as belonging to either a first or second group of patients, wherein said first group of patients having high levels of expression of the BAG gene is classified as having a different likelihood of suffering tumor recurrence or spread than said second group of patients having low levels of expression of the BAG gene.

10  
15

2. The method of claim 1, wherein said first group of patients having high levels of expression of the BAG gene are classified as having a decreased risk of tumor recurrence or spread compared to said second group of patients having low levels of expression of the BAG gene.

20

3. The method of claim 1, wherein said first group of patients having high levels of expression of the BAG gene are classified as having an increased risk of tumor recurrence or spread compared to said second group of patients having low levels of expression of the BAG gene.

25

4. The method of claim 1, wherein said second group of patients having low levels of expression of the BAG gene are classified as having a decreased risk of tumor recurrence or spread compared to said first group

30

of patients having high levels of expression of the BAG gene.

5. The method of claim 1, wherein said second group of patients having low levels of expression of the BAG gene are classified as having an increased risk of tumor recurrence or spread compared to said first group of patients having high levels of expression of the BAG gene.

6. The method of claim 1, wherein said expression level of the BAG gene is determined by measuring the amount of the BAG mRNA transcript or BAG protein.

7. The method of claim 6, wherein said measuring the amount of BAG protein is with an agent that binds BAG protein.

8. The method of claim 7, wherein said agent is an antibody specific for the BAG protein.

9. The method of claim 7, wherein said BAG protein is BAG-1.

10. The method of claim 7, wherein said BAG protein is BAG-1N.

11. The method of claim 6, wherein said expression level of the BAG gene is determined by measuring the amount of BAG protein product using an immunoassay.

12. The method of claim 11, wherein said immunoassay is an immuno-polymerase chain reaction (immuno-PCR) assay.

13. The method of claim 1, wherein said level of expression of the BAG gene is determined prior to lymph node involvement of said cancer.

14. The method of claim 1, wherein said level of expression of the BAG gene is determined after lymph node involvement of said cancer.

15. The method of claim 1, wherein said level of expression of the BAG gene is determined during Stage I or Stage II of said cancer.

16. A method for prognosis of disease-free or overall survival of an individual having a cancer tumor, comprising determining the level of BAG expression in a sample of said tumor or a body fluid, wherein a high level of expression correlates positively with disease-free or overall survival.

17. The method of claim 16, wherein said cancer is breast cancer.

18. The method of claim 16, wherein said level of BAG expression is determined by measuring the level of mRNA which encode said BAG protein.

19. The method of claim 16, wherein said level of BAG expression is determined by measuring BAG protein levels.

20. The method of claim 16, wherein said level of BAG expression is determined by measuring the level of BAG protein that is detectable in samples selected from the group consisting of breast tumor tissue, blood, serum, and plasma.

21. The method of claim 16, further comprising determining if said level of BAG expression represents an overproduction that is above a reference level of BAG expression.

5           22. The method of claim 21, wherein said reference level of BAG expression is determined by a histogram analysis.

          23. The method of claim 21, wherein said reference level of BAG expression is determined relative  
10 to a level of BAG expression produced by *in vitro* cultured cells which produce BAG.

          24. The method of claim 21, wherein said reference level of BAG expression is determined relative to a level of BAG expression in non-cancerous cells.

15           25. A method for predicting the risk of tumor recurrence or spread in an individual having a cancer tumor, comprising determining whether BAG protein is overproduced in a sample of said tumor or body fluid from said individual, such a production correlating with an  
20 increased likelihood of tumor recurrence or spread.

26. The method of claim 25, further comprising:

5 (a) determining an overproduction level for BAG protein, said level being in excess of a minimum amount statistically determined not to indicate a likelihood of tumor recurrence or spread;

(b) determining the level of BAG expression in said tumor sample; and

10 (c) predicting said risk of tumor recurrence or spread wherein an overproduction level of BAG protein in the tumor sample is associated with an increased likelihood of tumor recurrence or spread.

15 27. A method for screening a cancer patient to determine the risk of tumor metastasis, said method comprising:

20 (a) determining the level of amplification or expression of the BAG gene in a cancerous tissue sample or a body fluid sample from said patient; and

25 (b) classifying a patient having high levels of amplification or expression of the BAG gene, relative to a reference level, as being less likely to suffer tumor metastasis or having a increased chance of survival.

28. The method of claim 27, wherein said cancer is breast cancer.

29. The method of claim 27, wherein BAG amplification is measured with a probe specific for the BAG gene.

30. The method of claim 27, wherein gene  
5 expression is determined by measuring the amount of BAG mRNA transcription.

31. The method of claim 27, wherein gene expression is determined by measuring the amount of BAG protein.

10 32. The method of claim 31, wherein the amount of BAG protein is measured using an immunoassay.

33. The method of claim 32, wherein said immunoassay is an immuno-polymerase chain reaction assay.

34. A method for determining the proper course  
15 of treatment for a patient suffering from cancer, said method comprising:

(a) determining the level of BAG gene expression in a cancerous tissue sample or body fluid from said patient;

20 (b) identifying a first group of patients having low levels of BAG gene expression, which first group of patients may require treatment proper for patients having a lesser chance of survival or decreased time to tumor recurrence  
25 or spread; and

(c) identifying a second group of patients having high levels of BAG gene expression, which second group of patients may require treatment proper for patients having a greater chance of survival and being less likely to suffer tumor recurrence or spread.

35. The method of claim 34, wherein said level of BAG gene expression is determined by measuring the amount of BAG mRNA transcript or BAG protein.

36. The method of claim 34, wherein said level of BAG gene expression is determined prior to lymph node involvement.

37. The method of claim 34, wherein said level of expression of the BAG gene is determined after lymph node involvement of said cancer.

38. A kit for use in the method of claim 1, which includes one or more agents, each of which specifically bind to BAG protein, or fragments thereof.

39. The kit of claim 38, wherein said one or more agents comprise one or more antibodies.

40. A kit for use in the method of claim 1, which includes one or more nucleic acids, each of which specifically bind to BAG mRNA.



41. A reagent for use in the method of claim 1, comprising an antibody which specifically binds to the BAG protein, or fragments thereof.

42. The method of claim 1, wherein said cancer  
5 is breast cancer.

43. A method for determining a prognosis in a patient suffering from cancer, said method comprising:

(a) determining the level of expression of BAG in cancerous tissues of a patient; and

10 (b) classifying said patient as belonging either to a first group of patients having high levels of expression of BAG, or a second group of patients having low levels of expression of BAG;

15 wherein said first group and said second group have differing prognoses for tumor recurrence or spread.

44. The method of claim 43, wherein said first group has a lower likelihood of tumor recurrence or spread than said second group.

20 45. The method of claim 43, wherein said cancer is breast cancer.

46. A method for determining a prognosis in patients suffering from cancer, said method comprising classifying a first group of cancer patients having high  
25 levels of amplification or expression of BAG as having a different likelihood of tumor recurrence or spread than a

second group of patients having low levels of amplification or expression of BAG.

47. A method for monitoring the effectiveness of a course of treatment for a patient suffering from  
5 cancer, said method comprising:

(a) determining a first BAG gene expression level in a cancerous tissue sample or a body fluid sample from said patient prior to said treatment; and

10 (b) subsequently determining a second BAG gene expression level in a cancerous tissue sample or a body fluid sample from said patient during said treatment; and

whereby comparison of said first BAG expression level  
15 with said second BAG expression level indicates the effectiveness of said treatment.

48. A method for determining a prognosis of disease free or overall survival in a patient suffering from cancer, said method comprising:

20 (a) determining a BAG activity level in a cancerous tissue sample or body fluid sample from said patient; and

(b) classifying said patient as belonging to either a first or second group of patients, wherein said first group of patients having  
25 high levels of BAG activity is classified as having a different likelihood of suffering tumor recurrence or spread than said second group of patients having low levels of BAG  
30 activity.

49. The method of claim 48 wherein said determining a BAG activity level comprises determining levels of expression of Hip.

50. The method of claim 25 or 26, wherein said  
5 cancer is prostate cancer.

1/2




Fig. 1A




Fig. 1B

2/2




Fig. 2




Fig. 3

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/18758

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12Q1/68 G01N33/574

According to International Patent Classification (IPC) or to both national classification and IPC:

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12Q G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

WPI Data, PAJ, EPO-Internal, MEDLINE, BIOSIS, EMBASE, CHEM ABS Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No
X	TANG S-C. ET AL., : "Expression of BAG-1 in invasive breast carcinoma" J. CLIN. ONCOLOGY, vol. 17, no. 6, - June 1999 (1999-06) pages 1710-1719, XP000973837	1,16,25, 27,34, 38,41, 43,46,48
Y	the whole document ---	49
X	KRAJEWSKI S. ET AL.,: "Prognostic significance of apoptosis regulators in breast cancer" ENDOR RELAT CANCER, vol. 6, no. 1, - March 1999 (1999-03) pages 29-40, XP000973814 see whole doc. esp. abstarct and p. 34, 1.col. 1.par. ff.-p.37 last par. ---	1,16,25, 27,34, 38,41, 43,46-48
	-/--	



Further documents are listed in the continuation of box C



Patent family members are listed in annex

### Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance, the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*Z\* document member of the same patent family

Date of the actual completion of the international search

5 February 2001

Date of mailing of the international search report

28/02/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx 31 651 epo nl.  
Fax (+31-70) 340-3016

Authorized officer

Mueller, F

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/18758

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No
Y	BALLINGER C. ET AL.: "identification of chip, a novel tetratricopeptide repeat-containing protein that interacts with heat shock proteins and negatively regulates chaperone functions" MOL. CELL. BIOLOGY, vol. 19, no. 6, - June 1999 (1999-06) pages 4535-4545, XP002159196 the whole document	49
A	YANG X. ET AL.: "differentila expression of antiapoptotic gene BAG-1 in human breast normal and cancer cell lines and tissues" CLIN. CANCER. RESAERCH, vol. 5, July 1999 (1999-07), pages 1816-1822, XP000941979 see whole doc.esp. discussion	1,16,25, 27,34, 38,41, 43,48
A	WO 97 07387 A (BAR SHAVIT RACHEL :HADASIT MED RES SERVICE (IL)) 27 February 1997 (1997-02-27) see whole doc. esp. claims	1-50
A	WO 97 48982 A (CHILDRENS MEDICAL CENTER) 24 December 1997 (1997-12-24) see whole doc. esp. claims	1-50
A	WO 95 13292 A (JOLLA CANCER RES FOUND) 18 May 1995 (1995-05-18) see whole doc. esp. claims	1-50
A	TAKAYAMA S. ET AL.: "Expression and location of HSP70/Hsc binding anti-apoptotic protein BAG-1 and its variants in normal tissues and tumor cell lines" CANCER RESEARCH, vol. 58, no. 14, - 1998 pages 3116-3131, XP000941973 cited in the application see whole odc. esp. p.3127, 1.col., 1.par.ff., tabel 2,	1-50
P,X	WO 00 14106 A (BURNHAM INST) 16 March 2000 (2000-03-16) see whole doc. esp. claims, and p.23, line 7 ff. and p.37, line 12 ff., cl. 34	1,16,41, 43,46,48

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 00/18758

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9707387	A	27-02-1997	IL 114890 A	17-08-1999
			AU 6667496 A	12-03-1997
			CA 2229108 A	27-02-1997
			EP 0846263 A	10-06-1998
WO 9748982	A	24-12-1997	US 5858681 A	12-01-1999
			AU 723144 B	17-08-2000
			AU 3487497 A	07-01-1998
			CA 2257858 A	24-12-1997
			EP 0922223 A	16-06-1999
			JP 2000513098 T	03-10-2000
			US 6150117 A	21-11-2000
WO 9513292	A	18-05-1995	US 5539094 A	23-07-1996
			AU 687952 B	05-03-1998
			AU 1174295 A	29-05-1995
			CA 2176378 A	18-05-1995
			EP 0742793 A	20-11-1996
			JP 9509304 T	22-09-1997
			US 5686595 A	11-11-1997
			US 5650491 A	22-07-1997
			US 5641866 A	24-06-1997
WO 0014106	A	16-03-2000	AU 6038399 A	27-03-2000



RECD 15 NOV 2001

PCT

PCT

# INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference P 56542		<b>FOR FURTHER ACTION</b> See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/US00/18758	International filing date (day/month/year) 07/07/2000	Priority date (day/month/year) 09/07/1999	
International Patent Classification (IPC) or national classification and IPC C12Q1/00			
Applicant THE BURNHAM INSTITUTE et al.			

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.


2. This REPORT consists of a total of 10 sheets, including this cover sheet.

☐ This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of sheets.

3. This report contains indications relating to the following items:

- I ☒ Basis of the report
- II ☐ Priority
- III ☒ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- IV ☐ Lack of unity of invention
- V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☒ Certain documents cited
- VII ☒ Certain defects in the international application
- VIII ☒ Certain observations on the international application

Date of submission of the demand  06/02/2001	Date of completion of this report  13.11.2001
Name and mailing address of the international preliminary examining authority:   European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465	Authorized officer  Mueller, F  Telephone No. +49 89 2399 7722



**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International application No. PCT/US00/18758

**I. Basis of the report**

1. With regard to the **elements** of the international application (*Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17)*):

**Description, pages:**

1-52 as originally filed

**Claims, No.:**

1-50 as originally filed

**Drawings, sheets:**

1/3-3/3 as originally filed

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language: , which is:

- ☐ the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☐ contained in the international application in written form.
- ☐ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. The amendments have resulted in the cancellation of:

- ☐ the description, pages:
- ☐ the claims, Nos.:

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International application No. PCT/US00/18758

☐ the drawings, sheets:

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

*(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)*

6. Additional observations, if necessary:

**III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability**

1. The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non-obvious), or to be industrially applicable have not been examined in respect of:

☐ the entire international application.

☒ claims Nos. 10,43.

because:

☒ the said international application, or the said claims Nos. 43 relate to the following subject matter which does not require an international preliminary examination (*specify*):  
**see separate sheet**

☐ the description, claims or drawings (*indicate particular elements below*) or said claims Nos. are so unclear that no meaningful opinion could be formed (*specify*):

☒ the claims, or said claims Nos. 10 are so inadequately supported by the description that no meaningful opinion could be formed.

☐ no international search report has been established for the said claims Nos. .

2. A meaningful international preliminary examination cannot be carried out due to the failure of the nucleotide and/or amino acid sequence listing to comply with the standard provided for in Annex C of the Administrative Instructions:

☐ the written form has not been furnished or does not comply with the standard.

☐ the computer readable form has not been furnished or does not comply with the standard.

**V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**

1. Statement

Novelty (N)

Yes: Claims 12-14,18,23,28-33,36,37,40,49,50

# INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/US00/18758

	No:	Claims	1-9,11,15-17,19-22,24-27,34,35,38,39,41-48
Inventive step (IS)	Yes:	Claims	
	No:	Claims	1-50
Industrial applicability (IA)	Yes:	Claims	1-9,11-50 (43?)
	No:	Claims	

2. Citations and explanations  
**see separate sheet**

## VI. Certain documents cited

1. Certain published documents (Rule 70.10)

and / or

2. Non-written disclosures (Rule 70.9)

**see separate sheet**

## VII. Certain defects in the international application

The following defects in the form or contents of the international application have been noted:  
**see separate sheet**

## VIII. Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:  
**see separate sheet**

**Re Item III**

**Non-establishment of opinion with regard to novelty, inventive step and industrial applicability**

1. The term BAG-1N lacks support by the description and would appear meaningless to a skilled person. In the absence of further information regarding of the structural features of the underlying protein it is considered that the invention as regards claim 10 is not disclosed in a manner sufficiently clear and complete to be carried out by a person skilled in the art (Article 5 PCT).

2. Claim 43 relate to subject-matter considered by this Authority to be covered by the provisions of Rule 67.1(iv) PCT. Consequently, no opinion will be formulated with respect to the industrial applicability of the subject-matter of these claims (Article 34(4)(a)(i) PCT).

For the assessment of the present claim 43 on the question whether it is industrially applicable, no unified criteria exist in the PCT Contracting States. The patentability can also be dependent upon the formulation of the claims. The EPO, for example, does not recognize as industrially applicable the subject-matter of claims as far as an in vivo diagnostic method is concerned.

**Re Item V**

**Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**

1. The arguments presented by the applicant with the letter of 02.10.2001 have been taken into account.

2. Reference is made to the following documents:

D1: J. Clin. Oncology, Tang S.C. et al., 17(6), 1710-1719, xp973837

D2: Endor Relat Cancer, Krajewski S. et al., 6(1), 29-40, xp973814

D3: Clin. Cancer. Resaerch, Yang X. et al., 5, 1816-1822, xp941979

D4: Cancer Research, Takayama et al., 58, 15.07.1998, p.3116-3131, xp 941973

D5 : MCB, Ballinger et al., 19,6, 06.1999, p.4535-4545, xp 2159196

3. D1 describes the expression of BAG-1 in breast cancer tissue. The expression pattern and intensity of BAG-1 is not correlated with prognostic factors such as tumor size, grade histology, receptor status and stage. Furthermore disease-free and overall survival of patients whose tumors expresses BAG-1 were investigated (p. 1713, 2. col. , last par. ff.). The majority of breast cancer which express BAG-1 showed no correlation between its expression and conventional prognostic factors- therefore D1 discusses that BAG-1 may serve as an independent predictive factor in breast cancer prognosis. Its expression was significantly associated with a disease-free and overall survival in an multivariate analysis (see p. 1715). Furthermore it is discussed that the expression of nuclear BAG-1 shows a tendency to a less favourable outcome compared to tumor expressing cytoplasmic BAG-1 (p.1718,1. col. ff.). D1 furthers concludes that patients whose tumors over expressing BAG-1 may have a shorter survival and therefore may require a more aggressive treatment (p.1718, 2. col). The expression of BAG-1 is detected by using BAG-1 polyclonal antibody , sc 939 from Santa Cruz Biotechnology described on page 1711, last par., which is considered to be relevant prior art for the subject-matter of independent claims 38 and 41.

Therefore the subject matter of independent claims 1,16, 25, 27,34,38,41, 43, 46, 48 do not fulfil the requirements of novelty (Article 33 (2) PCT).

4. Furthermore independent claims 1,16, 25,27,34,38,41,43,46,47,48 do not fulfil the requirements of novelty (Article 33 (2) PCT) over the prior which is defined by D2. D2 describes the detection and localization of BAG-1 by immunostaining in early-stage breast cancers and its use as a prognostic marker in breast cancer. Higher levels of BAG-1 nuclear immunostaining correlates with longer overall survival among patients with early-stage breast cancer ( p. 36, 1.col). D2 discusses further the assessment of the nuclear expression of BAG-1 in breast cancer prior to, and during, therapies which could be correlated with less malignant phenotypes of mammary tumors (p. 37, 1. col, 3. par. ff.).

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT - SEPARATE SHEET**

---

International application No. PCT/US00/18758

5. The subject-matter of dependent claims 2 and 5,28,29,31,32,44,45 lacks novelty over D2 (Article 33 (2) PCT).  
D2 already describes that higher levels of BAG-1 expression is correlated with a longer survival (p.37, 1.col).
6. The subject-matter of dependent claims 3,4 and 26 lacks novelty over D1 (Article 33 (2) PCT).  
D1 already describes that patients with tumors over expressing BAG-1 have a shorter survival (p.1718, 2. col).
7. The subject-matter of dependent claims 6-9, 11,15 lacks novelty over D1 (Article 33 (2) PCT. D1 describes an immunostaining method for detecting BAG-1 expression levels (p. 1711, 2. col., 2. par.), e.g. during stages I-IV ( see table 4, p. 1718).
8. The subject-matter of dependent claims 17,19-22 and 24,35,39,42 lacks novelty over D2 (Article 33 (2) PCT. D2 already describes BAG-1 expression in breast cancer (p.34 ff.) and normal epithelium cells detected by immunostaining. Higher BAG-1 expression levels are correlated with a longer survival.
9. The subject-matter of dependent claims 18,23 and 37 lacks inventive step (Article 33(3)PCT).  
The detection of overexpressed genes in cancer is a common procedure in the technical field. D3 describes a Northern analysis of BAG-1 expression in breast carcinoma cell lines and normal cells (p.1817, fig.1 , 1.col.). Therefore the subject-matter of claims 18, 23 and 37 does not fulfil the requirements of Article 33 (3) PCT.
10. The subject-matter of dependent claims 12 and 33 refers to the method of immuno-PCR for detecting BAG proteins. The method of immuno-polymerase chain reaction is considered to be a common procedure in the field of immunology and therefore is not to be considered to involve an inventive step (Article 33 (3) PCT).
11. The subject-matter of dependent claims 13,14 and 36,37 refers to a method for

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/US00/18758

determining the expression pattern of the BAG gene prior or after lymph node involvement. Method for determining tumor progression by measuring the expression levels of cancer related genes prior and after lymph node metastases is already disclosed in D1 (p.1717, 2.col.). Therefore dependent claims 13,14 and 36,37 do not meet the requirements of inventiveness (Article 33 (3) PCT).

12. The subject-matter of dependent claims 30 and 40 refers to the detection of mRNA. D3 already describes Northern blot analysis using labeled BAG-1 cDNA probes for detection and quantifying BAG-1 RNA in carcinoma cells (See figure 1, 1817). Therefore the subject-matter of claims 30 and 40 does not fulfil the requirements of inventiveness (Article 33 (3) PCT).
13. The subject-matter of claim 49 refers to the correlation of BAG activity with the expression level of Hip. An eukaryotic reaction cycle in the presence of CHIP, Hsp40, Hip and BAG-1 is already described in D5. BAG-1 is connected to HIP by opposing the action of Hip and attenuating the Hsc70 chaperone activity (see discussion and fig. 10). Therefore it is obvious to a person skilled in the art that the BAG-1 activity is directly connected to the levels of Hip and therefore claim 49 does not fulfil the requirements of inventiveness (Article 33 (3) PCT).
14. The subject-matter of dependent claim 50 refers to the determination of BAG expression in prostate cancer. D4 already discusses different expression profiles of BAG-1 in different tumor cell lines , e.g. breast, colon, prostate etc. (table 2, p.3130). Therefore the detection of changes in the BAG expression levels in prostate cancer for determining the malignant transformation status of a patient does not involve an inventive step (Article 33 (3) PCT).

**Re Item VI**

**Certain documents cited**

**Certain published documents (Rule 70.10)**

Application No Patent No	Publication date (day/month/year)	Filing date (day/month/year)	Priority date (valid claim) (day/month/year)
WO-A1-0014106	16.03.2000	09.09.1999	09.09.1998



The intermediate document discloses a method of detecting BAG family proteins for determining the risk of metastatic spread of cancer or prognosis of cancer patients. This document, therefore, would appear to disclose or make obvious the subject-matter of claims 1,16,38,41,43,46 and 48.

However, it is assumed that the priority of the present application is validly claimed.

**Re Item VII**

**Certain defects in the international application**

1. Contrary to the requirements of Rule 5.1(a)(ii) PCT, the relevant background art disclosed in the documents D1,D2,D3 and D5 is not mentioned in the description, nor are these documents identified therein.
2. Page 1 lines 3-6 is irrelevant subject-matter according to Rule 9.1 (iv) PCT.
3. The specification for an international application should be self-contained without reference to any other document (cf PCT Guidelines, C-II, 4.17). The expression "incorporated herein by reference.." found in the description is therefore not according to the PCT requirements.

**Re Item VIII**

**Certain observations on the international application**

1. Although claims 1,16,43,46 and 48 have been drafted as separate independent claims, they appear to relate effectively to the same subject-matter and to differ from each other only with regard to the definition of the subject-matter for which protection is sought and/or in respect of the terminology used for the features of that subject-matter. The aforementioned claims therefore lack conciseness. Moreover, lack of clarity of the claims as a whole arises, since the plurality of independent claims makes it difficult, if not impossible, to determine the matter for which protection is sought, and places an undue burden on others seeking to establish the extent of the protection.

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT - SEPARATE SHEET**

---

International application No. PCT/US00/18758

Hence, claims 1,16,43,46 and 48 do not meet the requirements of Article 6 PCT.

2. The subject-matter of claims 38-40 is not clear (Article 6 PCT).

In the state of the art a kit is to be considered to contain a plurality of components which are necessary for carrying out a method. Claims 38-40 refers to a kit which includes one or more agents and therefore renders the subject-matter of the claims unclear.

## PATENT COOPERATION TREATY

## PCT

## INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference FP-LJ 4236	<b>FOR FURTHER ACTION</b> see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
International application No. PCT/US 00/ 18758	International filing date (day/month/year) 07/07/2000	(Earliest) Priority Date (day/month/year) 09/07/1999
Applicant  THE BURNHAM INSTITUTE et al.		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 3 sheets.

☒ It is also accompanied by a copy of each prior art document cited in this report.

## 1. Basis of the report

- a. With regard to the **language**, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

☐ the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

- b. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international search was carried out on the basis of the sequence listing :

☐ contained in the international application in written form.

☐ filed together with the international application in computer readable form.

☐ furnished subsequently to this Authority in written form.

☐ furnished subsequently to this Authority in computer readable form.

☐ the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

☐ the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

2. ☐ **Certain claims were found unsearchable** (See Box I).

3. ☐ **Unity of invention is lacking** (see Box II).

4. With regard to the **title**,

☒ the text is approved as submitted by the applicant.

☐ the text has been established by this Authority to read as follows:

5. With regard to the **abstract**,

☒ the text is approved as submitted by the applicant.

☐ the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the **drawings** to be published with the abstract is Figure No.

☐ as suggested by the applicant.

☐ because the applicant failed to suggest a figure.

☐ because this figure better characterizes the invention.

☒ None of the figures.

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/IS 00/18758

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 7 C12Q1/68 G01N33/574

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12Q G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

WPI Data, PAJ, EPO-Internal, MEDLINE, BIOSIS, EMBASE, CHEM ABS Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	TANG S-C. ET AL., : "Expression of BAG-1 in invasive breast carcinoma" J. CLIN. ONCOLOGY, vol. 17, no. 6, - June 1999 (1999-06) pages 1710-1719, XP000973837	1,16,25, 27,34, 38,41, 43,46,48
Y	the whole document	49
X	KRAJEWSKI S. ET AL.,: "Prognostic significance of apoptosis regulators in breast cancer" ENDOR RELAT CANCER, vol. 6, no. 1, - March 1999 (1999-03) pages 29-40, XP000973814 see whole doc. esp. abstarct and p. 34, 1.col. 1.par. ff.-p.37 last par.	1,16,25, 27,34, 38,41, 43,46-48

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*G\* document member of the same patent family

Date of the actual completion of the international search

5 February 2001

Date of mailing of the international search report

28/02/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel (+31-70) 340-2040. Tx. 31 651 epo nl.  
Fax (+31-70) 340-3016

Authorized officer

Mueller, F

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/18758

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No
Y	BALLINGER C. ET AL.,: "identification of chip, a novel tetratricopeptide repeat-containing protein that interacts with heat shock proteins and negatively regulates chaperone functions" MOL. CELL. BIOLOGY, vol. 19, no. 6, - June 1999 (1999-06) pages 4535-4545, XP002159196 the whole document	49
A	--- YANG X. ET AL.,: "differentila expression of antiapoptotic gene BAG-1 in human breast normal and cancer cell lines and tissues" CLIN. CANCER. RESAERCH, vol. 5, July 1999 (1999-07), pages 1816-1822, XP000941979 see whole doc.esp. discussion	1,16,25, 27,34, 38,41, 43,48
A	--- WO 97 07387 A (BAR SHAVIT RACHEL ;HADASIT MED RES SERVICE (IL)) 27 February 1997 (1997-02-27) see whole doc. esp. claims	1-50
A	--- WO 97 48982 A (CHILDRENS MEDICAL CENTER) 24 December 1997 (1997-12-24) see whole doc. esp. claims	1-50
A	--- WO 95 13292 A (JOLLA CANCER RES FOUND) 18 May 1995 (1995-05-18) see whole doc. esp. claims	1-50
A	--- TAKAYAMA S. ET AL.,: "Expression and location of HSP70/Hsc binding anti-apoptotic protein BAG-1 and its variants in normal tissues and tumor cell lines" CANCER RESEARCH, vol. 58, no. 14, - 1998 pages 3116-3131, XP000941973 cited in the application see whole odc. esp. p.3127, 1.col., 1.par.ff., tabel 2,	1-50
P,X	--- WO 00 14106 A (BURNHAM INST) 16 March 2000 (2000-03-16) see whole doc. esp. claims, and p.23, line 7 ff. and p.37, line 12 ff., cl. 34 -----	1,16,41, 43,46,48

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PO 00/18758

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9707387	A	27-02-1997	IL 114890 A	17-08-1999
			AU 6667496 A	12-03-1997
			CA 2229108 A	27-02-1997
			EP 0846263 A	10-06-1998
-----				
WO 9748982	A	24-12-1997	US 5858681 A	12-01-1999
			AU 723144 B	17-08-2000
			AU 3487497 A	07-01-1998
			CA 2257858 A	24-12-1997
			EP 0922223 A	16-06-1999
			JP 2000513098 T	03-10-2000
			US 6150117 A	21-11-2000
-----				
WO 9513292	A	18-05-1995	US 5539094 A	23-07-1996
			AU 687952 B	05-03-1998
			AU 1174295 A	29-05-1995
			CA 2176378 A	18-05-1995
			EP 0742793 A	20-11-1996
			JP 9509304 T	22-09-1997
			US 5686595 A	11-11-1997
			US 5650491 A	22-07-1997
			US 5641866 A	24-06-1997
-----				
WO 0014106	A	16-03-2000	AU 6038399 A	27-03-2000
-----				